# OnCo record orelabrutinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/orelabrutinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "orelabrutinib" ;
  schema:name "Orelabrutinib"@en ;
  schema:description "Orelabrutinib is InnoCare's BTK-blocking pill for chronic lymphocytic leukaemia and mantle cell lymphoma, approved in China in 2020."@en ;
  schema:url <https://onco.cc/drugs/orelabrutinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Orelabrutinib> ;
  schema:citation <https://www.innocarepharma.com/en>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule covalent BTK inhibitor (second generation)" ;
  schema:alternateName "Yinuokai" ;
  onco:approval "China 2020: Relapsed or refractory CLL/SLL; relapsed or refractory mantle cell lymphoma", "China 2023: Relapsed or refractory marginal zone lymphoma" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/innocare/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:trials <https://onco.cc/trials/nct06363994/>, <https://onco.cc/trials/nct06082102/>, <https://onco.cc/trials/nct04014205/> .